Abstract:Abstract. In total, 95% of primary tumors in the pancreas are epithelial tumors; primary mesenchymal tumors at this site are extremely rare. At present, only one comprehensive study about these rare tumors has been performed. Another retrospective analysis of these rare tumors is performed in the present study, which, to the best of our knowledge, is the first to be performed in China. In the present study, 10 patients that underwent resection for primary mesenchymal tumors of the pancreas were identified in a… Show more
“…and Kim et al. it was found that desmoid tumor was the most common benign mesenchymal pancreatic tumor, followed by solitary fibrous tumor [3] . The mean age of presentation is 36 years old and there is slight female to male predilection for abdominal DTs [4] .…”
Pancreas is an exceptionally rare location for desmoid tumors. There are very few case reports of pancreatic fibromatosis in the English radiology literature. We present a case of a 45-year-old male with a mixed solid and cystic desmoid tumor of the pancreas which was surgically resected and was followed by recurrence in the mesentery. This will be the first case report of pancreatic desmoid with documented recurrence of fibromatosis in the mesentery which was also surgically resected and confirmed on pathology. In this case report, we discuss this entity's radiological findings with pathology correlation, clinical findings and management along with literature review.
“…and Kim et al. it was found that desmoid tumor was the most common benign mesenchymal pancreatic tumor, followed by solitary fibrous tumor [3] . The mean age of presentation is 36 years old and there is slight female to male predilection for abdominal DTs [4] .…”
Pancreas is an exceptionally rare location for desmoid tumors. There are very few case reports of pancreatic fibromatosis in the English radiology literature. We present a case of a 45-year-old male with a mixed solid and cystic desmoid tumor of the pancreas which was surgically resected and was followed by recurrence in the mesentery. This will be the first case report of pancreatic desmoid with documented recurrence of fibromatosis in the mesentery which was also surgically resected and confirmed on pathology. In this case report, we discuss this entity's radiological findings with pathology correlation, clinical findings and management along with literature review.
“…The pancreatic origin DT remains an extremely rare subset of DTs. The English literature from the 1980s report 27 pancreatic DTs, and therefore our case is case number 28th [1] , [2] , [4] , [5] , [11] , [14] , [15] , [16] , [17] , [18] , [19] .…”
Introduction
Desmoid-type Fibromatoses (DTF) tumours are rare, benign fibrous tumours with aggressive invasive behaviour that account for approximately 0.03% of all neoplasms. We report the success in curing a rare, invasive, and huge pancreatic intraabdominal DTF.
Presentation of case
A 42 years old male was medically free apart from recurrent left upper abdominal pain, anorexia, and nausea for more than ten years and no significant past surgeries, trauma, or family history of cancer. The patient has a non-tender large abdominal mass at the left hypochondria area extending down to the pelvis below the umbilicus with a rigid and smooth surface. The computed tomography scan showed a huge heterogeneous mass appears to be of pancreatic origin, measuring about 23 cm by 15 cm by 11 cm. The patient underwent radical antegrade modular pancreato-splenectomy, segmental transverse colectomy, adrenalectomy, and subsequent colo-colic anastomosis. The accurate gross size of the tumour specimen was 26 × 17 × 9 cm, and the weight was found to be 3.6 kg. Immunohistochemistry confirmed the diagnosis of pancreas DTF. The follow up to 5 years confirmed no recurrence reported clinically or by imaging.
Discussion
The Pancreas origin of DTF is a rarely reported subset with an incidence of around 5% of all DTF. Establishing the diagnosis is fundamentally based on the characteristic pathological and immunohistochemical studies, for the only available cure modality by complete radical resection to be promptly offered.
Conclusion
Our case is rare and uniquely the largest pancreatic DTF reported in the literature with curative resection despite being locally invasive.
“…Presenting symptoms of primary pancreatic leiomyosarcomas may include abdominal pain, abdominal mass, weight loss, and jaundice, although the diagnosis is usually incidental [ 1 , 5 , 6 ]. Pancreatic leiomyosarcomas may be located in the pancreatic head, body, or tail [ 1 , 5 ]. These tumors are usually large in size at presentation [ 6 ].…”
Section: Discussionmentioning
confidence: 99%
“…Primary mesenchymal tumors of the pancreas are rare, with only 221 cases reported to date [ 1 ]. Primary pancreatic leiomyosarcomas are an even rarer subtype, with only 69 reported cases to date [ 2 ].…”
Primary pancreatic leiomyosarcoma and primary pancreatic leiomyoma are rare tumors of the pancreas. Primary pancreatic leiomyoma is a benign tumor and its conversion to leiomyosarcoma has never been reported. We report a case of malignant transformation of pancreatic leiomyoma. In this case, a 75-year-old male, who presented with a mass in the head of the pancreas, was diagnosed with primary pancreatic leiomyoma. The patient maintained well on symptomatic treatment for 13 years. However, later the patient presented with loss of appetite, significant weight loss, and an abdominal lump, which was diagnosed to be locally advanced primary pancreatic leiomyosarcoma. The patient was provided the best supportive care and died after 11 months of diagnosis. Hence, we conclude that a more radical treatment approach is needed in patients with primary pancreatic leiomyoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.